Pharma Capital

Akers Biosciences unveils raft of forthcoming potential board changes

It is also proposed that current chief executive John J. Gormally join the board
Picture of boardroom
The AGM will be on August 7 in Philadelphia, US

Akers Biosciences Inc (NASDAQ:AKER, LON:AKR) announced a raft of board changes that will be proposed at the group's forthcoming AGM.

Three new non-exec directors will be nominated - Bill J. White, Richard C. Tarbox III and Christopher C. Schreib.

Meanwhile, Thomas J. Knox, the current non-exec chair, Robert E. Andrews, Brandon Knox and Raza Bokhari, all non-executive directors,  will not stand for re-election and will retire from the board upon the election of the new directors.

READ: Akers Biosciences poised for growth in 2017

Executive director and current vice-chairman Raymond F. Akers Jr, is proposed to be re-elected as a director, and it is anticipated that he will become executive chairman upon his re-election.

It is also proposed that current chief executive John J. Gormally join the board as director - a role he does not currently have.

Regarding the proposed new directors, White has more than 30 years' experience in financial management, operations and business development, while Tarbox III has over 40 years of management experience in the medical device and diagnostics sector of the healthcare industry.

Schreiber has more than 30 years of experience in the securities industry, while Gormally has been Akers'  chief executive since November, 2015. He has over 30 years of experience as a member of senior management in the healthcare industry.

Giles_55af4ddca6481.jpg
Why Invest In Akers Biosciences, Inc.? Read More Here

Register here to be notified of future AKR Company articles
View full AKR profile

Akers Biosciences, Inc. Timeline

View All

Related Articles

© biotech Capital 2017

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.